It's no secret that the last year has been punishing.Are Pfizer's (PFE -0.04%) best days behind it? If the stock's critics are to be believed, the answer is an emphatic "yes, obviously," with issues like its recent stint of unprofitability and a beaten-down top line being the primary pieces of supporting evidence.But even the best companies can sometimes have a few quarters of difficulty, and investors should hesitate before counting this stock out. Let's analyze the arguments on each side and reach an acti ...

Pfizer (PFE) announced that a phase III study on its mini-dystrophin gene therapy fordadistrogene movaparvovec for treating Duchenne muscular dystrophy (“DMD”) failed to meet the primary endpoint as well as key secondary endpoints.The global phase III study, CIFFREO is investigating fordadistrogene movaparvovec in patients 4-8 years of age with DMD. A progressive and degenerative disorder, DMD leads to weakness and wasting away of the body’s muscles due to disruption of dystrophin production. The disease us ...

no_limit_picturesA difficult period for Pfizer (NYSE:PFE) might be coming to an end. The series of setbacks, such as the failures of the obesity pipeline during 2023, and the commercial underperformance that led to expectations reset with a “kitchen sink” guidance for 2024, are now behind us, and the COVID-19 franchise-led declines in revenues are finally in the rearview mirror. My share price bottom call from last year was premature, but I believe better times are ahead and that a return to growth led ...

Pfizer (PFE) closed the latest trading day at $27.66, indicating a -1.32% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.85%. Meanwhile, the Dow lost 0.09%, and the Nasdaq, a tech-heavy index, added 1.53%.Coming into today, shares of the drugmaker had lost 1.23% in the past month. In that same time, the Medical sector gained 2.46%, while the S&P 500 gained 3.11%.The upcoming earnings release of Pfizer will be of great interest to investors. The comp ...

Some say the art of investing is the ability of catching falling knives. Pfizer Inc. (PFE, Financial) shares have sold off in 2023 and represent an attractive opportunity after having likely bottomed out.Attractive opportunity despite poor stock performance The pharmaceutical company's dividend yield of approximately 5.80% naturally draws the attention of the market and seasoned investors alike. Approximately $9 billion is spent by the company in dividend payments per year, despite a free cash flow of only ...

These high-yield dividend payers have what it takes to pump up your portfolio's passive income stream.Billionaire investors generally don't necessarily need dividend income to make ends meet. They buy dividend-paying stocks because they know that companies committed to returning a portion of earnings to shareholders tend to outperform ones that don't.In the first three months of the year, billionaire hedge fund managers bought millions of shares of Pfizer (PFE -1.78%) and AT&T (T -1.33%).Both of these divid ...

Summary of Pfizer Inc. Conference Call Company Overview - **Company**: Pfizer Inc. (NYSE:PFE) - **Event**: Goldman Sachs 45th Annual Global Healthcare Conference - **Date**: June 10, 2024 - **Participants**: Albert Bourla (Chairman and CEO), Chris Shibutani (Goldman Sachs) Key Points 1. Stock Performance and Strategic Plan - 2023 was a challenging year for Pfizer's stock performance, leading to a strategic plan announced for 2024 focusing on five key priorities [3] - Integration of Seagen to develop oncology leadership is progressing well, with Q1 results showing growth in the oncology business despite typical merger challenges [3] - Emphasis on evolving the pipeline, particularly in oncology, with multiple readouts expected by year-end [3] - Focus on maximizing performance of new product launches, with measures taken to improve commercial operations [3] - Capital allocation priorities include maintaining dividends, de-leveraging the balance sheet, and investing in business growth [3] 2. Leadership Changes - Appointment of Andrew as a key strategic partner for the leadership team, expected to bring fresh ideas and critical perspectives [5] - Andrew's role includes overseeing strategy, business development, and capital prioritization for the pipeline [5] 3. Oncology Focus - Oncology is highlighted as a central focus area, with the Seagen acquisition being the largest in a decade and expected to be highly successful [9] - Seagen's technology, particularly antibody-drug conjugates (ADCs), is seen as a significant asset, with multiple products in the market and a robust pipeline [9] - The integration of Seagen is reported to be successful, with a dedicated team ensuring innovation is maintained [10] 4. Pipeline and Product Development - Pfizer is focusing on both pipeline development and the performance of existing oncology products [12] - The company has significant products in breast cancer (IBRANCE) and prostate cancer (XTANDI), with ongoing development of new therapies [17] - Interest in various modalities, including small molecules and bispecific antibodies, while remaining open to emerging science [19] 5. COVID-19 and Vaccine Strategy - Pfizer believes that combining COVID-19 and flu vaccines could enhance penetration in the market, especially among younger populations [21] - The company anticipates that 90% of respiratory-driven vaccine sales will occur in the second half of the year [23] - Despite challenges in forecasting COVID revenues, Pfizer remains confident in meeting its numbers for the year [23] 6. RSV Vaccine Performance - Pfizer's RSV vaccine performance exceeded budget expectations, but market share was lower than desired compared to competitors [25] - The company is renegotiating contracts to improve market positioning for the upcoming flu season [26] 7. Metabolic Disease and Obesity - Pfizer maintains a strong interest in metabolic diseases, particularly obesity, and is investing in this area despite previous setbacks [28] - The company has multiple molecules in development, with a focus on oral therapies [30] 8. Business Development and Acquisitions - Pfizer is currently in a "breathing period" after significant investments in acquisitions, focusing on executing existing strategies rather than pursuing large new acquisitions [32] - Smaller tuck-in acquisitions may still occur, particularly in oncology and obesity [32] 9. Regulatory Environment - Concerns about the impact of the Inflation Reduction Act (IRA) on revenue forecasting and strategic planning, particularly regarding small versus large molecules [34] - Pfizer is adapting its strategy to favor large molecules due to the regulatory landscape [37] 10. Brand Equity and Marketing - The decision to invest in a Super Bowl commercial was made to enhance brand equity, especially following the Seagen acquisition [39] - Pfizer's brand recognition is seen as a significant asset in the market [39] Conclusion - Pfizer is navigating a complex landscape with a focus on oncology, strategic leadership changes, and adapting to regulatory challenges while maintaining a commitment to innovation and market leadership. The company is optimistic about its future performance and growth potential across various therapeutic areas.

Massimo Giachetti My thesis Pfizer (NYSE:PFE) was one of few pharmaceutical companies which were able to develop the COVID-19 vaccine within a short period, and I was very surprised to find out that the stock currently trades below pre-pandemic levels. Data by YCharts The business looks solid as the revenue mix is diverse across various geographies, diseases and products. Despite recent dip in profitability, it is still stellar and enables the company to pour billions per annum in developing new products. T ...

CAMBRIDGE, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate atirmociclib, Pfizer’s investigative selective-CDK4 inhibitor, in combination with RLY-2608 and fulvestrant in patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer. ...

CAMBRIDGE, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate atirmociclib, Pfizer’s investigative selective-CDK4 inhibitor, in combination with RLY-2608 and fulvestrant in patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer. ...